Eli Lilly (LLY) financial statements
+249.8%since 2007
- FY2025 revenue
- $65.2B▲ +44.7%
- FY2025 net income
- $20.6B▲ +94.9%
- FY2025 diluted EPS
- $22.95▲ +96.0%
- FY2025 free cash flow
- $9.0B▲ +138.6%
Eli Lilly income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 65,179 | 45,043 | 34,124 |
| Pretax income | 25,731 | 12,680 | 6,554 |
| Net income | 20,640 | 10,590 | 5,240 |
| Diluted earnings per share | 22.95 | 11.71 | 5.80 |
Eli Lilly balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 7,268 | 3,268 | 2,819 |
| Total assets | 112,476 | 78,715 | 64,006 |
| Total liabilities (derived) | 85,941 | 64,443 | 53,143 |
| Total equity | 26,535 | 14,272 | 10,864 |
| Long-term debt | 40,868 | 28,527 | 18,321 |
Eli Lilly cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 16,813 | 8,818 | 4,240 |
| Capital expenditure | -7,841 | -5,058 | -3,448 |
| Free cash flow (derived) | 8,972 | 3,760 | 792 |
| Dividends paid | -5,384 | -4,680 | -4,069 |
| Share repurchases | -4,108 | -2,500 | -750 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 24,397 | 22,974 | 19,799 | 19,292 |
| Net income (derived) | 6,451 | 7,095 | 7,396 | 6,638 |
| Diluted earnings per share | 7.22 | 7.94 | 8.26 | n/a |
| Operating cash flow (derived) | 11,397 | 10,690 | 5,333 | 3,225 |
| Total assets | 148,072 | 142,283 | 116,576 | 112,476 |
Eli Lilly major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| LILLY ENDOWMENT INC | 10.1% | 96,016,978 | 16 April 2025 |
| LILLY ENDOWMENT, INC. | 9.6% | 90,066,978 | 19 October 2026 |
| Vanguard Capital Management | 6.5% | 61,295,605 | 1 May 2026 |
| THE PNC FINANCIAL SERVICES GROUP, INC. | 5.4% | 51,153,837 | 7 February 2025 |
Eli Lilly 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 29 October 2026 | 10-Q | Quarterly report | Quarterly report |
| 29 October 2026 | 8-K | Current report | Current report |
| 5 August 2026 | 10-Q | Quarterly report | Quarterly report |
| 5 August 2026 | 8-K | Current report | Current report |
| 20 May 2026 | 8-K | Current report | Current report |
| 7 May 2026 | 8-K | Current report | Current report |
| 30 April 2026 | 10-Q | Quarterly report | Quarterly report |
| 30 April 2026 | 8-K | Current report | Current report |
Common questions
What was Eli Lilly's revenue in fiscal 2025?
Eli Lilly reported $65.2 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 44.7% from fiscal 2024.
What was Eli Lilly's net income in fiscal 2025?
Eli Lilly reported net income of $20.6 billion for fiscal 2025, the year ended 31 December 2025, up 94.9% from fiscal 2024. Diluted earnings per share were $22.95.
What was Eli Lilly's free cash flow in fiscal 2025?
Eli Lilly had $9.0 billion in free cash flow in fiscal 2025. Operating cash flow was $16.8 billion and capital expenditure was $7.8 billion.
What were Eli Lilly's total assets at the end of fiscal 2025?
Eli Lilly reported total assets of $112.5 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Eli Lilly history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.